Ryaltris Spray, Metered
Product Images NDC 59467-700

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Ryaltris (NDC 59467-700). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Specialty Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ctn.jpg (Ctn)

Ctn.jpg (Ctn)
Ryaltris is a nasal spray for intranasal use only. It contains olopatadine hydrochloride and mometasone furoate at 665 mcg/25 mcg per spray. Each metered spray delivers 100 mg of suspension containing 865 mcg olopatadine hydrochloride, equivalent to 600 mcg olopatadine as base, and 25 mcg mometasone furoate. The contents are an aqueous suspension containing various ingredients. It is recommended to shake the bottle well before each use. The initial priming requires spraying until a fine mist appears, and the reprime requires spraying until a fine mist appears only if Ryaltris has not been used for 14 days. The dosage should be prescribed by a doctor. The storage instructions advise not to store in the freezer or refrigerator, and keep it out of reach of children. The dosing instructions include blowing one's nose and tilting the head while spraying while inhaling gently. Two sprays per nostril are recommended, and Ryaltris should be discarded after 240 actuations. The package contains 29g net fill weight and 240 metered sprays. For additional assistance, one can call 1-800-962-8364 or visit WRYALTRIS.com. The product is distributed by Hikma Specialty USA Inc, Columbus, OH 63228.*
FDA Label Image

Figurea.jpg (Figurea)

Figurea.jpg (Figurea)
This is likely a list of items related to a "spray pump unit". It includes a "dust cap", "spray pump tip", "finger rest", and a "bottle". The context and purpose of these items cannot be determined without further information.*
FDA Label Image

Figureb.jpg (Figureb)

FDA Label Image

Figurec.jpg (Figurec)

FDA Label Image

Figured.jpg (Figured)

FDA Label Image

Figuree.jpg (Figuree)

FDA Label Image

Figuref.jpg (Figuref)

FDA Label Image

Figureg.jpg (Figureg)

FDA Label Image

Figureh.jpg (Figureh)

FDA Label Image

Figurei.jpg (Figurei)

FDA Label Image

Figurej.jpg (Figurej)

FDA Label Image

Figurek.jpg (Figurek)

FDA Label Image

Figurel.jpg (Figurel)

FDA Label Image

Lbl.jpg (Lbl)

Lbl.jpg (Lbl)
This text provides instructions and information on using RYALTRIS nasal spray for intranasal use only. The user is instructed to prime the spray with six sprays or until a fine mist appears before each use and to use two sprays or until a fine mist appears following a storage period of more than 14 days. The recommended dosage for the prescription medication is not provided and users are instructed to refer to the prescribing information. Storage instructions indicate that the nasal spray should be kept upright with the dust cap on at a controlled room temperature and should not be stored in the refrigerator or freezer. The product contains olopatadine hydrochloride and mometasone furoate and features 665 mcg/25 mcg per spray with a net fill weight of 29 g.*
FDA Label Image

Structure-mometasone.jpg (Structure Mometasone)

FDA Label Image

Structure-olopatadine.jpg (Structure Olopatadine)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.